Physician profile
Melody Lin
NPI 1396295051
$1,697.40
in general payments reported to CMS, 2019-2025
16 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $713 · 2023: $375 · 2024: $194 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.19 | 2023-2025 | Jardiance |
| Abbvie INC. | $129.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $120.16 | 2021 | |
| Glaxosmithkline, LLC. | $111.12 | 2024 | Shingrix |
| Teva Pharmaceuticals USA, INC. | $110.94 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $106.58 | 2022 | |
| Sumitomo Pharma America, INC. | $104.69 | 2023 | Gemtesa |
| Exeltis, USA INC. | $103.35 | 2025 | Twirla, Slynd |
| Jazz Pharmaceuticals INC. | $100.04 | 2022 | |
| Amgen INC. | $99.02 | 2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $94.69 | 2022 | |
| Genzyme Corporation | $88.38 | 2023 | |
| Novo Nordisk INC | $87.03 | 2022 | |
| Biogen, INC. | $83.26 | 2024 | Skyclarys |
| Edwards Lifesciences Corporation | $81.30 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $71.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.